[Asia Economy Reporter Yoo Hyun-seok] Intops is on the rise. It appears to be influenced by its role in casing and packaging in the production of SD Biosensor's COVID-19 diagnostic kits.
As of 9:12 AM on the 8th, Intops was trading at 34,250 KRW, up 2.24% (750 KRW) compared to the previous trading day.
Recently, photos of SD Biosensor's diagnostic kits have been circulating on online communities. The photos show the seller as Hanmi Pharm, the manufacturing requester as SD Biosensor, and the manufacturer as Intops.
A company official explained, "We are responsible for the casing and packaging parts in the production of SD Biosensor's COVID-19 diagnostic kits."
Meanwhile, SD Biosensor is currently conducting a public offering for listing on KOSDAQ. The demand forecast for institutional investors held on the 5th and 6th recorded a competition rate of 1,144 to 1. A total of 1,389 domestic and foreign institutions participated. Accordingly, the public offering price was set at the upper end of the desired price range (45,000 KRW to 52,000 KRW), at 52,000 KRW.
The company increased the public offering volume by about 20% due to the success of the demand forecast. The final number of shares offered is 14,930,400, raising the total public offering amount to 776.4 billion KRW. The market capitalization after listing is 5.3701 trillion KRW based on the confirmed public offering price. The subscription for general investors will be held on the 8th and 9th. Subscriptions can be made through the lead underwriters NH Investment & Securities and Korea Investment & Securities.
SD Biosensor is a diagnostic kit specialized company originating from SD, established in 1999. With the spread of COVID-19, its sales scale rapidly grew, recording sales of 1.6862 trillion KRW and operating profit of 738.3 billion KRW last year. In the first quarter of this year, it already achieved sales of 1.1871 trillion KRW, reaching about 70% of last year's annual sales.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
